跳至主要内容
临床试验/EUCTR2017-001731-39-IT
EUCTR2017-001731-39-IT进行中(未招募)1 期

Methodology study to investigate the utility of retroviral insertion site analysis in samples from subjects treated with Strimvelis™ gene therapy - Retroviral insertion site methodology study

Orchard Therapeutics (Europe) Ltd0 个研究点目标入组 15 人开始时间: 2020年7月2日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Male or female, paediatric or adult, patients with ADA-SCID, who have been previously treated with Strimvelis or GSK2696273
  • Informed Consent
  • 2.Capable of giving signed informed consent as described in Appendix 2 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Or signed informed consent provided by the participant’s parent or legal guardian.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 2
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1.Presence of concomitant condition(s) that in the Investigator’s opinion makes participation in the study unsuitable or may prevent compliance with the protocol requirements.
  • 2.Unlikely to comply with the requirements of the protocol (i.e. attendance for blood sampling on an approximately annual basis)
  • 3.Transportation of viable samples to the EU central laboratory from the participant’s home country is not possible

研究者

相似试验

Retroviral insertion site methodology study | 临床试验